Catalog No.
EVV24012
Expression system
Mammalian cells
Species
Influenza B virus (B/Singapore/En246/2014)
Protein length
Leu37-Leu466
Predicted molecular weight
75.23 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
A0A126UEI1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for one week. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Neuraminidase, NA
Seroprevalence of anti-influenza antibodies in humans and characterization of seasonal influenza viruses isolated in Russia during the 2023-2024 flu season., PMID:40307541
Dual roles of influenza B virus neuraminidase mRNA vaccine in enhancing cross-lineage protection by supplementing inactivated split vaccination., PMID:40265888
A monoclonal anti-hemagglutinin stem antibody modified with zanamivir protects against both influenza A and B viruses., PMID:40193611
Neuraminidase-specific antibodies drive differential cross-protection between contemporary FLUBV lineages., PMID:40153499
High-resolution melting analysis for detection of nucleotide mutation markers in the polymerase-acidic (PA) gene of influenza virus that are associated with baloxavir marboxil resistance., PMID:39762649
Antiviral Effect of Amentoflavone Against Influenza Viruses., PMID:39596490
Influenza neuraminidase mutations and resistance to neuraminidase inhibitors., PMID:39530458
Genetic characterization of influenza B virus and oseltamivir resistance in pediatric patients with acute respiratory infections: a cross-sectional study., PMID:39499431
Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA., PMID:39379405
Molecular epidemiology and vaccine compatibility analysis of seasonal influenza A viruses in the context of COVID-19 epidemic in Wuhan, China., PMID:39370830
Triton X-100-treated virus-based ELLA demonstrates discordant antigenic evolution of influenza B virus hemagglutinin and neuraminidase., PMID:39360825
The evolutionary features and roles of single nucleotide variants and charged amino acid mutations in influenza outbreaks during NPI period., PMID:39223292
Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses., PMID:39171925
The Development History, Structural Composition, and Functions of Influenza Viruses and the Progress of Influenza Virus Inhibitors in Clinics and Clinical Trials., PMID:39113298
Molecular epidemiology and phylogenetic analysis of influenza viruses A (H3N2) and B/Victoria during the COVID-19 pandemic in Guangdong, China., PMID:39090685
Genomic evolution of influenza during the 2023-2024 season, the johns hopkins health system., PMID:39079210
Resurgence of influenza with increased genetic diversity of circulating viruses during the 2022-2023 season., PMID:39073070
Genetic Reassortment in a Child Coinfected with Two Influenza B Viruses, B/Yamagata Lineage and B/Victoria-Lineage Strains., PMID:38932274
Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface., PMID:38823390
Influenza Virus Genomic Surveillance, Arizona, USA, 2023-2024., PMID:38793574
Discovery of new antiviral agents through artificial intelligence: In vitro and in vivo results., PMID:38280564
Clinical characteristics of outpatients with influenza-B-associated pneumonia and molecular evolution of influenza B virus in Beijing, China, during the 2021-2022 influenza season., PMID:38233704
Influenza B virus neuraminidase: a potential target for next-generation vaccines?, PMID:38037386
Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody., PMID:37515226
Anti-neuraminidase and anti-hemagglutinin immune serum can confer inter-lineage cross protection against recent influenza B., PMID:36689429
Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner., PMID:36299418
Molecular characterization and evolution dynamics of influenza B viruses circulating in Germany from season 1996/1997 to 2019/2020., PMID:36096395
[Expression of influenza B virus hemagglutinin and its immunogenicity determination]., PMID:35355478
Antiviral activity of Epimedium koreanum Nakai water extract against influenza viruses., PMID:34965505
Functionality of the putative surface glycoproteins of the Wuhan spiny eel influenza virus., PMID:34697321
Molecular Characterization of Seasonal Influenza A and B from Hospitalized Patients in Thailand in 2018-2019., PMID:34070388
Epitope-targeting platform for broadly protective influenza vaccines., PMID:34043704
Molecular Docking Studies and Biological Evaluation of Berberine-Benzothiazole Derivatives as an Anti-Influenza Agent via Blocking of Neuraminidase., PMID:33673431
Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective., PMID:32976769
Fitness of influenza A and B viruses with reduced susceptibility to baloxavir: A mini-review., PMID:32975358
Hsa-miR-30e-3p inhibits influenza B virus replication by targeting viral NA and NP genes., PMID:32878461
Adaptation of influenza B virus by serial passage in human airway epithelial cells., PMID:32853848
Antiviral potential of garlic (Allium sativum) and its organosulfur compounds: A systematic update of pre-clinical and clinical data., PMID:32836826
A single N342D substitution in Influenza B Virus NA protein determines viral pathogenicity in mice., PMID:32746754
Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus., PMID:32631823
Novel oseltamivir-resistant mutations distant from the active site of influenza B neuraminidase., PMID:32406800
Experimental Infection Using Mouse-Adapted Influenza B Virus in a Mouse Model., PMID:32326238
Evolutionary dynamics of influenza B strains detected from paediatric acute respiratory infections in central Vietnam., PMID:32105864
The Structure, Function, and Pathobiology of the Influenza A and B Virus Ion Channels., PMID:31988204
Antigenic variants of influenza B viruses isolated in Japan during the 2017-2018 and 2018-2019 influenza seasons., PMID:31955521
Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection., PMID:31941786
[The model of prediction of the inhibition of neuraminidases of influenza A and B based on a reduced set of energy terms]., PMID:31876523
The Quest for a Truly Universal Influenza Vaccine., PMID:31649895
Broadly protective human antibodies that target the active site of influenza virus neuraminidase., PMID:31649200
Influenza A and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies., PMID:31590935
For research use only. Not for human or drug use.
